Ozempic vs Mounjaro
GLP-1 Receptor Agonist (semaglutide) · Dual GIP/GLP-1 Receptor Agonist (tirzepatide)
Here is how these two compounds compare, based on published research, not marketing claims.
Ozempic
Novo Nordisk's brand of semaglutide. FDA-approved for type 2 diabetes. The only weight-loss-class GLP-1 with completed cardiovascular outcomes data through the SELECT trial.
Mounjaro
Eli Lilly's brand of tirzepatide. FDA-approved for type 2 diabetes. The first dual GIP and GLP-1 receptor agonist, with the largest weight reduction shown in any approved diabetes medication.
Ozempic
4520 studies
39 human trials
FDA-Approved
Mounjaro
1849 studies
47 human trials
FDA-Approved
What it does
Ozempic
Ozempic is the Novo Nordisk brand of semaglutide indicated by the FDA for type 2 diabetes, with cardiovascular benefit demonstrated in adults with established heart disease. It works by telling the brain the body is full and slowing how fast the stomach empties. The same active ingredient is sold as Wegovy at a higher dose, with FDA approval for chronic weight management.
Mounjaro
Mounjaro is the Eli Lilly brand of tirzepatide indicated by the FDA for type 2 diabetes. It activates two appetite and metabolism receptors at once (GIP and GLP-1) instead of just one, the dual mechanism that distinguishes tirzepatide from earlier GLP-1 medications. The same active ingredient is sold as Zepbound at higher doses, with FDA approval for chronic weight management.
How it works
Ozempic
Ozempic delivers semaglutide, a modified copy of GLP-1, a hormone the body releases naturally after eating. The molecule activates the GLP-1 receptor in the brain and gut, which tells the brain the body is full, slows how fast the stomach empties, and helps the pancreas release insulin when blood sugar is high. A fatty acid modification on the molecule extends how long it stays active in the body, which is what allows for less frequent dosing than natural GLP-1 would require.
Mounjaro
Mounjaro delivers tirzepatide, a synthetic peptide that acts as an agonist at both GIP receptors and GLP-1 receptors simultaneously. The GLP-1 side mirrors what semaglutide does: tells the brain the body is full, slows gastric emptying, helps the pancreas release insulin when blood sugar is high. The GIP side adds enhanced fat metabolism and may distribute the pharmacological load across two receptor systems. The dual mechanism produced greater HbA1c and weight reduction than semaglutide 1mg in the SURPASS-2 head-to-head trial.
How often
Ozempic
FDA labeling specifies once-weekly subcutaneous injection from a pre-filled pen for Ozempic. Trial protocols across the SUSTAIN program and clinical use specify gradual dose titration over several months, which the labeling notes is associated with improved GI tolerability. Novo Nordisk also markets a daily oral semaglutide formulation (Rybelsus) with FDA approval for type 2 diabetes.
Mounjaro
FDA labeling specifies once-weekly subcutaneous injection from a pre-filled pen for Mounjaro. The SURPASS trial protocols and FDA prescribing information specify gradual dose titration over several months, which the labeling notes is associated with improved GI tolerability.
How strong
Ozempic
Strong glycemic control and meaningful weight reduction at FDA-approved doses for type 2 diabetes. The SUSTAIN program established the diabetes efficacy. The SELECT trial extended the case to cardiovascular outcomes, demonstrating reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease. Patients commonly experience appetite suppression and slower gastric emptying as the dose titrates up.
Mounjaro
The largest weight reduction in any approved type 2 diabetes medication based on the SURPASS program. Patients commonly experience pronounced appetite suppression as the dose titrates up. The dual GIP plus GLP-1 mechanism produces effects that GLP-1-only medications do not, including the larger glycemic and weight-loss numbers seen in SURPASS-2.
Main tradeoff
Ozempic
Ozempic carries the deepest evidence base in the GLP-1 class: completed Phase III programs across diabetes (SUSTAIN, PIONEER) and cardiovascular outcomes (SELECT), plus the longest real-world safety record. Common side effects are GI: nausea, vomiting, diarrhea, usually transient and dose-dependent. Tirzepatide (Mounjaro) produced larger average HbA1c and weight reductions in the SURPASS-2 head-to-head trial, but Ozempic remains the only weight-loss-class GLP-1 with completed cardiovascular outcomes data. Bone mineral density may decrease modestly with significant weight loss; the effect is class-shared with tirzepatide and appears weight-loss-mediated rather than drug-specific (Liu et al. 2026). In patients with diabetes (Ozempic's FDA-approved population), bone density loss was similar to matched controls.
Mounjaro
Mounjaro produced superior HbA1c and weight reduction compared with Ozempic 1mg in head-to-head data (SURPASS-2). The trade-off is evidence maturity: tirzepatide is newer, with less long-term safety data than semaglutide and no completed cardiovascular outcomes trial yet (SURPASS-CVOT is ongoing). Common side effects are GI: nausea, vomiting, diarrhea, similar in pattern to GLP-1 agonists but potentially differing due to dual-receptor activity. Bone mineral density may decrease modestly with significant weight loss; the effect is class-shared with semaglutide and appears weight-loss-mediated rather than drug-specific (Liu et al. 2026). In patients with diabetes (Mounjaro's FDA-approved population), bone density loss was similar to matched controls.
Best for
Ozempic
- Adults with type 2 diabetes and established cardiovascular disease prioritizing the SELECT outcomes data
- Patients seeking the GLP-1 with the longest real-world safety record and most mature post-marketing surveillance
- Clinical contexts where insurance covers Ozempic but not Mounjaro at preferred-tier
Mounjaro
- Adults with type 2 diabetes seeking superior HbA1c reduction and combined weight reduction
- Adults with type 2 diabetes prioritizing the dual GIP/GLP-1 mechanism over the longer post-marketing safety record of semaglutide
- Clinical contexts where insurance covers Mounjaro but not Ozempic at preferred-tier
How to choose
A good fit for Ozempic
- Type 2 diabetes patients with established cardiovascular disease where the SELECT outcomes data is decision-relevant
- Patients prioritizing the GLP-1 with the longest real-world safety record
- Insurance contexts where Ozempic is the preferred-tier formulary option
- Patients with a history of dose-titration sensitivity who benefit from Ozempic's longer pharmacovigilance record
A good fit for Mounjaro
- Type 2 diabetes patients seeking the larger HbA1c and weight reduction shown in SURPASS-2 head-to-head data
- Patients seeking the dual GIP plus GLP-1 mechanism for combined glycemic and metabolic effect
- Insurance contexts where Mounjaro is the preferred-tier formulary option
- Type 2 diabetes patients prioritizing the dual GIP/GLP-1 mechanism over the longer post-marketing safety record of semaglutide
Consider both across time
Ozempic and Mounjaro are both FDA-approved as type 2 diabetes medications. The choice often comes down to insurance coverage and physician familiarity. Tirzepatide produced superior HbA1c and weight reduction in head-to-head data (SURPASS-2 used semaglutide 1mg, not the higher 2mg now common in clinical practice), but semaglutide has cardiovascular outcomes data tirzepatide hasn't matched yet. Neither carries an FDA approval for weight loss under these brand names: that approval lives with their sibling brands, Wegovy (semaglutide for obesity) and Zepbound (tirzepatide for obesity).
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GLP-1 Receptor
- GLP-1 Receptor activates GLP-1 Signaling
- GLP-1 Signaling connects to Appetite + Gastric Emptying
- GLP-1 Signaling connects to Glucose Control
- Appetite + Gastric Emptying connects to Weight + Glycemic Outcomes; Glucose Control connects to Weight + Glycemic Outcomes; Appetite + Fat Metabolism connects to Weight + Glycemic Outcomes
- GIP Receptor
- GLP-1 Receptor activates Dual GIP + GLP-1 Signaling; GIP Receptor activates Dual GIP + GLP-1 Signaling
- Dual GIP + GLP-1 Signaling connects to Appetite + Fat Metabolism
Ozempic (semaglutide) activates the GLP-1 receptor in the brain and gut, which tells the brain the body is full and slows how fast the stomach empties.
Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors at once. The GLP-1 side mirrors Ozempic; the GIP side adds enhanced fat metabolism.
Research Evidence
Both Ozempic and Mounjaro sit at PSI's highest evidence tier (FDA Approved). Ozempic has the deeper, longer evidence base: completed Phase III programs across diabetes (SUSTAIN), oral semaglutide (PIONEER), and cardiovascular outcomes (SELECT). Mounjaro's evidence base is substantial but newer: the SURPASS program established efficacy for type 2 diabetes, with the parallel cardiovascular outcomes trial (SURPASS-CVOT) ongoing. Head-to-head data from SURPASS-2 showed Mounjaro produced greater HbA1c and weight reduction than Ozempic 1mg over 40 weeks; the higher Ozempic 2mg dose now common in clinical practice was not part of that head-to-head.
- 1.
For type 2 diabetes patients with established cardiovascular disease, Ozempic has the SELECT trial outcomes data; Mounjaro's parallel SURPASS-CVOT is ongoing.
- 2.
For patients seeking the larger HbA1c and weight reduction shown in head-to-head data, Mounjaro produced greater reductions than Ozempic 1mg in SURPASS-2.
- 3.
For weight loss as the primary clinical goal, the FDA-approved formulations of these compounds are sold under different brand names: Wegovy (semaglutide) and Zepbound (tirzepatide).
- 4.
Both brands require physician prescription and ongoing supervision for dose titration, side effect monitoring, and discontinuation planning. Insurance coverage and physician familiarity often drive the practical brand choice.
Key Limitations
- •SURPASS-2 head-to-head compared tirzepatide doses to semaglutide 1mg, not the higher 2mg Ozempic dose now common in clinical practice; direct head-to-head data at maximum diabetes doses does not exist.
- •Mounjaro's parallel cardiovascular outcomes trial (SURPASS-CVOT) has not reported.
- •Long-term (5+ year) post-marketing safety data is more mature for Ozempic than for Mounjaro.
- •Insurance coverage, formulary tier, and supply constraints affect real-world access and may influence prescribing decisions independent of efficacy data.
- •Compounded versions of both active ingredients are not FDA-approved and are subject to pharmacy regulations that have changed multiple times since 2023.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Ozempic
"I lost 30+ pounds on Ozempic without changing anything else"
Supported by evidence
"Ozempic face is a real thing. I look ten years older"
Supported by evidence
"The nausea goes away after a few weeks"
Supported by evidence
Mounjaro
"Mounjaro is stronger than Ozempic for weight loss"
Supported by evidence
"The dual agonist mechanism is why it works better"
Supported by evidence
"Tirzepatide has fewer GI side effects than semaglutide"
Plausible but limited comparison data
Safety Comparison
Both share the GLP-1 class side effect profile: nausea, vomiting, diarrhea, usually transient and dose-dependent, and manageable with slow dose titration. Both carry the FDA boxed warning for thyroid C-cell tumors based on rodent studies; clinical relevance in humans remains debated. Ozempic has the longer real-world safety record and more extensive post-marketing surveillance through Novo Nordisk's pharmacovigilance program. Mounjaro's dual-receptor mechanism is newer; long-term safety is still being characterized as more years of post-approval data accumulate. On bone density: both compounds appear to cause modest bone mineral density loss in head-to-head data (Liu et al. 2026, J Clin Endocrinol Metab), with the loss correlating with weight loss within the GLP-1 RA group rather than a direct drug effect; in patients with diabetes (the FDA-approved population for both brands), bone density loss was similar to matched controls. Compounded versions of either active ingredient are not FDA-approved and have been associated with dosing errors and quality concerns outside the FDA-regulated supply chain.
Ozempic
Well-characterized safety profile from multiple Phase III programs (SUSTAIN, PIONEER, SELECT). Most common adverse events are GI-related: nausea, vomiting, diarrhea, typically transient and dose-dependent. FDA boxed warning for thyroid C-cell tumors based on rodent studies; clinical relevance in humans debated. Rare risks include pancreatitis.
Mounjaro
Safety profile from the SURPASS program. GI adverse events similar in pattern to GLP-1 agonists but potentially differing due to dual-receptor activity. FDA boxed warning for thyroid C-cell tumors based on rodent studies. Long-term post-marketing data is growing but less extensive than semaglutide's.
What the Research Suggests
Ozempic and Mounjaro are both FDA-approved type 2 diabetes medications at the highest evidence tier. The choice between them is rarely about whether they work: both do, with strong randomized controlled trial evidence. It's about which evidence profile matches the clinical question. Mounjaro produced larger HbA1c and weight reductions than Ozempic 1mg in head-to-head data. Ozempic has cardiovascular outcomes data Mounjaro hasn't matched yet. For patients searching by brand name without realizing the FDA-approved indication is type 2 diabetes (not weight loss), the appropriate weight-loss-indicated brands are Wegovy and Zepbound. PSI does not endorse one brand over the other; the appropriate choice depends on the individual clinical context, which a physician evaluates.